Navigation Links
Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
Date:3/13/2008

s, the conduct and results of future clinical trials, plans regarding regulatory filings, future research, discovery of new product candidates, and clinical trials, and plans regarding partnering and outlicensing activities and the participation at upcoming scientific conferences. Factors that may cause actual results to differ materially include the risk that product candidates that appeared promising in early research and clinical trials do not demonstrate safety or efficacy in larger- scale or later clinical trials, the risk that the Company will not obtain approval to market its products, the risks associated with reliance on outside financing to meet capital requirements, the risks associated with reliance on collaborative partners for future revenues under the terms of its existing collaboration agreements, the risks associated with further clinical trials, development and commercialization of product candidates, and the risks associated with recruiting and retention of individuals in key management functions. You are urged to consider statements that include the words "may," "will," "would," "could," "should," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal," or the negative of those words or other comparable words to be uncertain and forward-looking. These factors and others are more fully discussed in Micromet's periodic reports and other filings with the SEC, including the "Risk Factors" sections of such reports.

Any forward-looking statements are made pursuant to Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and, as such, speak only as of the date made. Micromet undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

Micromet, Inc.


'/>"/>

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results
2. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
3. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
4. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
5. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
6. Helix BioPharma reports Q2 2008 highlights, financial results
7. Oncothyreon reports full year and fourth quarter 2007 financial results
8. Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure
9. Alfacell Reports Financial Results for Second Quarter of Fiscal 2008
10. ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
11. Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... The Alliance for Clinical Research Excellence and Safety ... public interest, and Texas-based for-profit San Antonio Express-News ... formed a strategic alliance to create a blog as ... healthcare and clinical research endeavor. The blog provides ... public to be clearly heard in this important dialogue. ...
(Date:5/4/2015)... SAN FRANCISCO, Calif. , May 4, 2015 ... clinical-stage biopharmaceutical company focused on the development and ... diseases, announced today the completion of its merger ... 4). In conjunction with the closing of the ... from a combination of new investors and all ...
(Date:5/4/2015)...   St. Jude Children,s Research Hospital ... for finding genetic alterations that play an important ... identify with whole-genome sequencing. The findings appear today ... The tool is an algorithm called ... Tree in Next Generation Sequencing. ...
(Date:5/4/2015)... 2015  Tikcro Technologies Ltd. (OTCQB: TIKRF) announced today ... 20-F for the fiscal year ended December 31, 2014 ... annual report on Form 20-F contains information regarding its ... area of cancer immune checkpoints. This project aims to ... and binding in targeting certain identified immune checkpoints. The ...
Breaking Biology Technology:ACRES and San Antonio Express-News Launch Blog on Accountability in Clinical Research 2ACRES and San Antonio Express-News Launch Blog on Accountability in Clinical Research 3ACRES and San Antonio Express-News Launch Blog on Accountability in Clinical Research 4Tobira Therapeutics Completes Financing and Merger with Regado Biosciences 2Tobira Therapeutics Completes Financing and Merger with Regado Biosciences 3Tobira Therapeutics Completes Financing and Merger with Regado Biosciences 4Tobira Therapeutics Completes Financing and Merger with Regado Biosciences 5Tobira Therapeutics Completes Financing and Merger with Regado Biosciences 6Scientists dramatically improve method for finding common genetic alterations in tumors 2Scientists dramatically improve method for finding common genetic alterations in tumors 3Scientists dramatically improve method for finding common genetic alterations in tumors 4Tikcro Technologies Files Annual Report on Form 20-F for the Year Ended December 31, 2014 2
... Genzyme Corp. said on Wednesday it has agreed ... Wisconsin-Madison biotech spinoff, for $600 million in cash. , ,Bone ... more than $2 billion and almost 7,000 employees worldwide, plan ... companies recently reported healthy quarterly profits and revenues. Bone Care ...
... a new copy machine for $57,000. , ,The Z-Corp ... typical office copier: It makes three-dimensional models of small structures ... , ,Using white polymer powder and colored inks, the printer ... a time. Z-Corp is headquartered in Burlington, Massachusetts. , , ...
... can submit executive summaries of their businesses for angel ... May 9. , ,The Wisconsin Angel Network ... investor networks with entrepreneurs based on the investors' market ... a deal-flow pipeline, has been designed to be a ...
Cached Biology Technology:Massachusetts firm to buy UW spinoff Bone Care for $600 million 2Massachusetts firm to buy UW spinoff Bone Care for $600 million 3Start-ups, angels can connect on new state Web site 2Start-ups, angels can connect on new state Web site 3
(Date:4/20/2015)... 2015 Huntington Memorial Hospital is the first ... new miniaturized, wireless monitoring sensor to manage heart failure ... only FDA-approved heart failure monitoring device that has been ... physicians to manage heart failure. The CardioMEMS ... the pulmonary artery (PA) during a non-surgical procedure to ...
(Date:4/14/2015)... April 14, 2015  HYPR Corp. today announced ... ® ) Alliance tm , an industry consortium ... commit to share technology and collaborate to deliver ... interoperable, more secure and private, and easier to ... verification that protects sensitive user information and eliminates ...
(Date:4/13/2015)... 2015  higi, a leading cloud-based consumer engagement platform ... engage with their communities around health and wellness, announced ... secure API.  ... affordable, and convenient vehicle to receive validated health information ... The API will allow higi,s trusted partners, on ...
Breaking Biology News(10 mins):Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3
... industries. They focus light to zap tumors and send digital ... But the physical length of an ordinary laser cannot be ... which limits its application in many industries. Now the Spaser, ... can be as small as needed to fuel nano-technologies of ...
... REDWOOD CITY, Calif., Jan. 12, 2011 The ... biocatalysts and services, and secures supply of Codexis ... routes developed by DSM,s InnoSyn™ route scouting services. ... efficient manufacturing processes for active pharmaceutical ingredients and ...
... common virus-killing material significantly more effective is a breakthrough from ... Rather than trying to turn the process into profit, ... hope wide adoption will save time, money and perhaps even ... in Environmental Science and Technology , an American Chemical ...
Cached Biology News:The 'Spaser' heats up laser technology 2DSM and Codexis Sign Enzyme Supply Agreement 2DSM and Codexis Sign Enzyme Supply Agreement 3DSM and Codexis Sign Enzyme Supply Agreement 4Virus killer gets supercharged 2Virus killer gets supercharged 3
... The Z-Competent E. coli Transformation Buffer Set ... competent E. coli cells for simple and ... completely eliminates the requirement for heat shocking ... can be performed by adding DNA to ...
... The Light Diagnostics Universal Amplicon ... for use in the qualitative ... generated by in vitro ... use only; not to be ...
Propidium Iodide: {3,8-diamino-5-[3-(diethylmethylammonio)propyl]-6-phenylphenanthridinium diodide}. Antifade Solution: p-Phenylenediamine and glycerol in PBS solution. 2.5ug/mL Propidium Iodide (PI)...
Apoptosis Detection Systems and Reagents...
Biology Products: